Clinical trials: Advanced Malignant Cancer
Advanced Malignant Solid Tumors
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821…
- Trial name
- NCT05773937
- Testing
- 9MW2821
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Neoplasms, Malignant
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
Primary Objective: To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of ombrabulin in combination with docetaxel and cisplatin administered every 3 weeks in…
- Trial name
- NCT01095302
- Testing
- OMBRABULIN (AVE8062), cisplatin, docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Sanofi
Advanced Cancer
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in…
- Trial name
- NCT03459222
- Testing
- Relatlimab, Nivolumab, BMS-986205
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be…
- Trial name
- SCLC (NCT05271292)
- Testing
- Chiauranib
- Where
- 11 sites in United States
- Volunteers
- 36 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Advanced/Metastatic Malignant Solid Tumors
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 in patients with advanced/metastatic solid tumors.
- Trial name
- NCT06115642
- Testing
- HLX43, HLX10
- Where
- 14 sites in United States, China and 1 more
- Volunteers
- 367 people
- Sponsor
- Shanghai Henlius Biotech
Malignant Melanoma
CP-675,206 In Patients With Advanced Melanoma
The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma
- Trial name
- NCT00086489
- Testing
- CP-675,206
- Where
- 9 sites in United States
- Volunteers
- 118 people
- Sponsor
- AstraZeneca
Malignant Solid Tumor
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug…
- Trial name
- NCT01606748
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Advanced Malignant Solid Tumors
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors
- Trial name
- NCT03792958
- Testing
- CM082
- Where
- China
- Volunteers
- 19 people
- Sponsor
- AnewPharma
Solid Tumors, Adult, Solid Tumor
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally…
- Conditions
- Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE)
- Trial name
- NCT05228015
- Testing
- IK-930, Osimertinib
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- Ikena Oncology
Advanced Cancer
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.
- Trial name
- NCT03446040
- Testing
- BMS-986258, Nivolumab, rHuPH20
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.
- Trial name
- NCT03792750
- Testing
- BMS-986205, Nivolumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb